ZLATO INC Inactive Instrument
Zlato Inc Share Price OTC Bulletin Board
Equities
US98977G1076
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2019 | Vilacto Bio Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019 | CI |
| 2019 | Vilacto Bio Inc. Reports Earnings Results for the Full Year Ended March 31, 2019 | CI |
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Gert Andersen
CEO | Chief Executive Officer | 54 | 24/17/24 |
Poul Madsen
CTO | Chief Tech/Sci/R&D Officer | 61 | 10/17/10 |
| Chief Operating Officer | 49 | 10/17/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gert Andersen
CEO | Chief Executive Officer | 54 | 24/17/24 |
Vilacto Bio Inc., formerly Zlato Inc., is a biotechnology company engaged in the business of skincare products. The Company has developed Lactoactive, which is processing of colostrum combined with hyaluronic acid. Lactoactive contains hyaluronic acid, which penetrates the skin, regenerates damaged skin cells and restores elasticity. The Company provides treatment for various diseases, including inflammatory disorders & anti-inflammatory treatments, immune system factors, psoriasis, vitiligo, autoimmune related skin conditions, systemic lupus erythematosus (SLE) disease, blistering skin disease and diabetic ulcers disease. The Company sells its products under the name Vilact. The Company also sells its products through its Website www.vilactobio.com. The Company has operations in New York in the United States, Naestved in Denmark and Lithuania.
| 1st Jan change | Capi. | |
|---|---|---|
| +27.14% | 42.68B | |
| -2.94% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +7.11% | 24.94B | |
| -20.60% | 18.96B | |
| +28.92% | 12.3B | |
| -2.46% | 11.95B | |
| -1.21% | 11.55B |
